Sansure Biotech
a STAR Market-listed Chinese in-vitro diagnostics company that scaled domestic point-of-care molecular testing manufacturing and distribution capacity, continuing as a leading domestic IVD platform provider.
- Country
- China
Commercial
Domestic POCT molecular platforms
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Point-of-care molecular diagnostics | diagnostics-medtech | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.